Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Neutralization: Anti-Mouse VEGF Receptor 2 has the ability to neutralize the biological activity of recombinant mouse VEGF Receptor 2 on HUVE (human umbilical vein endothelial) cells in the presence of recombinant mouse VEGF Receptor 2/Fc (50 ng/mL) and recombinant mouse VEGF (5 ng/mL).
Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
KDR (FLK1, VEGFR2) is a type III receptor tyrosine kinase. It binds vascular endothelial growth factor with high affinity in vitro, and is expressed early in development by endothelial cell precursors. FLK1 (VEGF Receptor 2) encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of FLK1 (VEGF Receptor 2) are implicated in infantile capillary hemangiomas.
仅用于科研。不用于诊断过程。未经明确授权不得转售。